Market Overview:
The global Lewy body dementia drugs market is expected to register a CAGR of 7.8% during the forecast period, 2018-2030. The growth in the market can be attributed to factors such as increasing prevalence of Lewy body dementia, rising geriatric population, and technological advancements in drug delivery systems. However, the high cost of treatment is expected to restrain the growth of this market during the forecast period. Based on type, benzodiazepine is projected to be the fastest growing segment during the forecast period. This can be attributed to its ability to improve sleep quality and reduce anxiety symptoms associated with Lewy body dementia. Based on application, hospital pharmacies are estimated to account for a larger share of this market in 2018 owing to increased awareness about these drugs among healthcare professionals and patients alike.
Product Definition:
Lewy body dementia drugs are medications prescribed to people who have been diagnosed with Lewy body dementia. These drugs are important because they can help improve the symptoms of the disease.
Modafinil:
Modafinil is a eugeroic used for the treatment of sleep disorders and narcolepsy. It works by increasing wakefulness and alertness during sleep deprivation, thus providing an effective remedy against insomnia as well as cataplexy in narcoleptic patients.
Benzodiazepine:
Benzodiazepine is a class of drug used to treat sleep disorders and anxiety. It works by enhancing the calming effect of GABA ( Gamma-aminobutyric acid) in the brain. Benzodiazepines are generally prescribed for people who have been diagnosed with social anxiety disorder, panic disorder, agoraphobia, or who are experiencing severe insomnia.
Application Insights:
Based on application, the market is segmented into hospital pharmacies, retail pharmacies and online pharmacies. The online pharmacy segment dominated the overall industry in terms of revenue in 2017. This may be attributed to factors such as increasing internet usage rates and growing use of smartphones which provide access to health information globally. Moreover, an increase in healthcare awareness among people has resulted in increased demand for generic drugs which are available without a prescription through online channels only.
The hospital pharmacy segment is expected to witness significant growth over the forecast period owing to rising incidences of BDD worldwide coupled with high product penetration due largely to government regulations that require pharmacists at hospitals dispensing medication for patients suffering from dementia or Lewy body disorders. In addition, an increase in healthcare awareness among people has resulted in increased demand for generic drugs which are available without a prescription through hospital channels only ¢â‚¬Å“ eSPRESSOSAURUS by Teva Pharmaceuticals USA Inc.
Regional Analysis:
North America dominated the global Lewy body dementia drugs market in 2017. The presence of key players, favorable government initiatives and increasing healthcare expenditure are some of the factors contributing to its growth. For instance, in 2014, Novartis AG launched a clinical trial for evaluating the efficacy of Riluzole in patients with Alzheimer’s disease psychosis. This was followed by GlaxoSmithKline Plc., who initiated a similar study for their brand name drug Riluzole (Zoloft). Such initiatives are expected to increase awareness about LBD and thus drive demand over the forecast period.
Growth Factors:
- Increasing prevalence of Lewy body dementia
- Growing awareness about Lewy body dementia
- Rising demand for better treatment options for Lewy body dementia
- increasing research and development activities for new drugs to treat Lewy body dementia
- growing number of collaborations between pharmaceutical companies and research institutes to develop new drugs for the treatment of lewy body dementias
Scope Of The Report
Report Attributes
Report Details
Report Title
Lewy Body Dementia Drugs Market Research Report
By Type
Modafinil, Benzodiazepine, Antidepressants, Cholinesterase Inhibitors, Antipsychotic Drugs, Carbidopa-Levodopa
By Application
Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
By Companies
Novartis, Pfizer, Bayer, GlaxoSmithKline, Mylan, Sanofi, Johnson & Johnson, Teva Pharmaceuticals, Eli Lilly, Eisai, Takeda Pharmaceutical, Allergan, Bausch Health Companies, BioArctic, Sumitomo Dainippon Pharma, Jazz Pharmaceuticals, Hisamitsu Pharmaceutical
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
247
Number of Tables & Figures
173
Customization Available
Yes, the report can be customized as per your need.
Global Lewy Body Dementia Drugs Market Report Segments:
The global Lewy Body Dementia Drugs market is segmented on the basis of:
Types
Modafinil, Benzodiazepine, Antidepressants, Cholinesterase Inhibitors, Antipsychotic Drugs, Carbidopa-Levodopa
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Novartis
- Pfizer
- Bayer
- GlaxoSmithKline
- Mylan
- Sanofi
- Johnson & Johnson
- Teva Pharmaceuticals
- Eli Lilly
- Eisai
- Takeda Pharmaceutical
- Allergan
- Bausch Health Companies
- BioArctic
- Sumitomo Dainippon Pharma
- Jazz Pharmaceuticals
- Hisamitsu Pharmaceutical
Highlights of The Lewy Body Dementia Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Modafinil
- Benzodiazepine
- Antidepressants
- Cholinesterase Inhibitors
- Antipsychotic Drugs
- Carbidopa-Levodopa
- By Application:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Lewy Body Dementia Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Lewy body dementia drugs are medications that are used to treat the symptoms of Lewy body dementia. These drugs can help improve memory, thinking skills, and movement.
Some of the key players operating in the lewy body dementia drugs market are Novartis, Pfizer, Bayer, GlaxoSmithKline, Mylan, Sanofi, Johnson & Johnson, Teva Pharmaceuticals, Eli Lilly, Eisai, Takeda Pharmaceutical, Allergan, Bausch Health Companies, BioArctic, Sumitomo Dainippon Pharma, Jazz Pharmaceuticals, Hisamitsu Pharmaceutical.
The lewy body dementia drugs market is expected to register a CAGR of 7.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Lewy Body Dementia Drugs Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Lewy Body Dementia Drugs Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Lewy Body Dementia Drugs Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Lewy Body Dementia Drugs Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Lewy Body Dementia Drugs Market Size & Forecast, 2018-2028
4.5.1 Lewy Body Dementia Drugs Market Size and Y-o-Y Growth
4.5.2 Lewy Body Dementia Drugs Market Absolute $ Opportunity
Chapter 5 Global Lewy Body Dementia Drugs Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Lewy Body Dementia Drugs Market Size Forecast by Type
5.2.1 Modafinil
5.2.2 Benzodiazepine
5.2.3 Antidepressants
5.2.4 Cholinesterase Inhibitors
5.2.5 Antipsychotic Drugs
5.2.6 Carbidopa-Levodopa
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Lewy Body Dementia Drugs Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Lewy Body Dementia Drugs Market Size Forecast by Applications
6.2.1 Hospital Pharmacies
6.2.2 Retail Pharmacies
6.2.3 Online Pharmacies
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Lewy Body Dementia Drugs Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Lewy Body Dementia Drugs Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Lewy Body Dementia Drugs Analysis and Forecast
9.1 Introduction
9.2 North America Lewy Body Dementia Drugs Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Lewy Body Dementia Drugs Market Size Forecast by Type
9.6.1 Modafinil
9.6.2 Benzodiazepine
9.6.3 Antidepressants
9.6.4 Cholinesterase Inhibitors
9.6.5 Antipsychotic Drugs
9.6.6 Carbidopa-Levodopa
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Lewy Body Dementia Drugs Market Size Forecast by Applications
9.10.1 Hospital Pharmacies
9.10.2 Retail Pharmacies
9.10.3 Online Pharmacies
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Lewy Body Dementia Drugs Analysis and Forecast
10.1 Introduction
10.2 Europe Lewy Body Dementia Drugs Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Lewy Body Dementia Drugs Market Size Forecast by Type
10.6.1 Modafinil
10.6.2 Benzodiazepine
10.6.3 Antidepressants
10.6.4 Cholinesterase Inhibitors
10.6.5 Antipsychotic Drugs
10.6.6 Carbidopa-Levodopa
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Lewy Body Dementia Drugs Market Size Forecast by Applications
10.10.1 Hospital Pharmacies
10.10.2 Retail Pharmacies
10.10.3 Online Pharmacies
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Lewy Body Dementia Drugs Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Lewy Body Dementia Drugs Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Lewy Body Dementia Drugs Market Size Forecast by Type
11.6.1 Modafinil
11.6.2 Benzodiazepine
11.6.3 Antidepressants
11.6.4 Cholinesterase Inhibitors
11.6.5 Antipsychotic Drugs
11.6.6 Carbidopa-Levodopa
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Lewy Body Dementia Drugs Market Size Forecast by Applications
11.10.1 Hospital Pharmacies
11.10.2 Retail Pharmacies
11.10.3 Online Pharmacies
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Lewy Body Dementia Drugs Analysis and Forecast
12.1 Introduction
12.2 Latin America Lewy Body Dementia Drugs Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Lewy Body Dementia Drugs Market Size Forecast by Type
12.6.1 Modafinil
12.6.2 Benzodiazepine
12.6.3 Antidepressants
12.6.4 Cholinesterase Inhibitors
12.6.5 Antipsychotic Drugs
12.6.6 Carbidopa-Levodopa
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Lewy Body Dementia Drugs Market Size Forecast by Applications
12.10.1 Hospital Pharmacies
12.10.2 Retail Pharmacies
12.10.3 Online Pharmacies
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Lewy Body Dementia Drugs Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Lewy Body Dementia Drugs Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Lewy Body Dementia Drugs Market Size Forecast by Type
13.6.1 Modafinil
13.6.2 Benzodiazepine
13.6.3 Antidepressants
13.6.4 Cholinesterase Inhibitors
13.6.5 Antipsychotic Drugs
13.6.6 Carbidopa-Levodopa
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Lewy Body Dementia Drugs Market Size Forecast by Applications
13.10.1 Hospital Pharmacies
13.10.2 Retail Pharmacies
13.10.3 Online Pharmacies
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Lewy Body Dementia Drugs Market: Competitive Dashboard
14.2 Global Lewy Body Dementia Drugs Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Novartis
14.3.2 Pfizer
14.3.3 Bayer
14.3.4 GlaxoSmithKline
14.3.5 Mylan
14.3.6 Sanofi
14.3.7 Johnson & Johnson
14.3.8 Teva Pharmaceuticals
14.3.9 Eli Lilly
14.3.10 Eisai
14.3.11 Takeda Pharmaceutical
14.3.12 Allergan
14.3.13 Bausch Health Companies
14.3.14 BioArctic
14.3.15 Sumitomo Dainippon Pharma
14.3.16 Jazz Pharmaceuticals
14.3.17 Hisamitsu Pharmaceutical
